High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase

Liu, Yanwei; Li, Yanong; Wang, Peng; Chen, Li; Jin, Feng; Qiu, Xiaoguang

doi:10.1186/s13014-021-01878-3

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with an IDH mutation/1p/19q non-codeletion or wild-type IDH may have improved survival with the administration of high-dose radiotherapy 22 , 23 . Moreover, MGMT status is an independent prognostic biomarker of LGGs treated with radiotherapy 24 . Therefore, molecular classification plays an important role in predicting radiotherapy effects, and new trials should be designed in the current molecular era.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas

Liu

Chen

et al. 2022

Cancer Biol Med

View full text Add to dashboard Cite

Objective: IDH-mutant lower-grade gliomas (LGGs, grade 2 or 3) eventually transform into secondary grade 4 astrocytomas (sAIDHmut/G4). Here, we sought to describe the transformation time, risk factors, and outcomes in malignant transformation of IDH-mutant LGGs. Methods: We screened data for 108 patients with sAIDHmut/G4 in the Chinese Glioma Genome Atlas who had initial IDH-mutant LGGs and underwent reoperation during 2005–2021. We evaluated the transformation time from IDH-mutant LGGs to sAIDHmut/G4, and associated risk factors and outcomes. Malignant transformation was defined as pathological confirmation of grade 4 astrocytoma. Results: The median age of the 108 patients with IDH-mutant LGGs was 35 years (range, 19–54); the median age at transformation was 40 years (range, 25–62); and the median follow-up time for all patients was 146 months (range, 121–171). The average transformation time was 58.8 months for all patients with LGGs (range, 5.9–208.1); 63.5 and 51.9 months for grade 2 and 3 gliomas, respectively; and 58.4 and 78.1 months for IDH-mutant/1p/19q-non-codeleted astrocytomas and IDH-mutant/1p/19q-codeleted oligodendrogliomas, respectively. Univariate and multivariate analysis indicated that radiotherapy [hazard ratio (HR), 0.29; 95% confidence interval (CI), 0.137–0.595; P = 0.001] and non-A blood type (HR, 0.37; 95% CI, 0.203–0.680; P = 0.001) were protective factors against delayed malignant transformation. Radiotherapy was associated with improved survival after transformation (HR, 0.44; 95% CI, 0.241–0.803; P = 0.008), overall survival (HR, 0.50; 95% CI, 0.265–0.972; P = 0.041), and progression-free survival (HR, 0.25; 95% CI, 0.133–0.479; P < 0.0001) in patients with IDH-mutant gliomas. Conclusions: Radiotherapy is associated with delayed malignant transformation and improved survival in patients with IDH-mutant gliomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas

Liu

Chen

et al. 2022

Cancer Biol Med

View full text Add to dashboard Cite

show abstract

“…The standard dose of radiation for DMGs is typically around 54-60 Gy and may reach up to 66-70 Gy based on case characteristics; it is delivered over the course of several weeks [118][119][120][121].…”

Section: Radiotherapymentioning

confidence: 99%

Decoding Diffuse Midline Gliomas: A Comprehensive Review of Pathogenesis, Diagnosis and Treatment

Al Sharie,

Abu Laban,

Al-Hussaini

2023

Cancers

View full text Add to dashboard Cite

Diffuse midline gliomas (DMGs) are a group of aggressive CNS tumors, primarily affecting children and young adults, which have historically been associated with dismal outcomes. As the name implies, they arise in midline structures in the CNS, primarily in the thalamus, brainstem, and spinal cord. In more recent years, significant advances have been made in our understanding of DMGs, including molecular features, with the identification of potential therapeutic targets. We aim to provide an overview of the most recent updates in the field of DMGs, including classification, molecular subtypes, diagnostic techniques, and emerging therapeutic strategies including a review of the ongoing clinical trials, thus providing the treating multidisciplinary team with a comprehensive understanding of the current landscape and potential therapeutic strategies for this devastating group of tumors.

show abstract

CACA guidelines for holistic integrative management of glioma

Fan

Jiang

et al. 2022

Holist Integ Oncol

View full text Add to dashboard Cite

Glioma of the brain is a kind of tumor originating from neuroglial cells. It is the most common primary intracranial tumor, accounting for ~ 30% of all central nervous system tumors and 80% of malignant brain tumors. Glioma is characterized by high disability and recurrence rates. The disease seriously threatens the life of patients, affects their quality of life, and brings a heavy economic and psychological burden to patients, families, and society.With the progression of molecular genetic testing technology and the completion of various clinical trials, the classification scheme for glioma is increasingly well established. Diagnosis and treatment regimens, including traditional and new regimens, are becoming increasingly specialized and standardized. The purpose is to develop a clinical diagnosis and treatment guideline for glioma in the Chinese population suitable for Chinese doctors and the general population based on domestic and international glioma research progress. Thus, domestic practitioners in the field can obtain current information and provide better service to patients with glioma, promoting the development of domestic clinical medicine and basic research on glioma.

show abstract

High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase

Cited by 4 publications

References 30 publications

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas

Decoding Diffuse Midline Gliomas: A Comprehensive Review of Pathogenesis, Diagnosis and Treatment

CACA guidelines for holistic integrative management of glioma

Contact Info

Product

Resources

About